EUVIMEDEUVIMED entdecken
Open Access

Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes

Alexander J Moody, Marjorie Molina-Wilkins, Geoffrey D Clarke, Aurora Merovci, Carolina Solis-Herrera, Eugenio Cersosimo iD, Robert J Chilton, Patricia Iozzo, Amalia Gastaldelli iD, Muhammad Abdul-Ghani iD, Ralph A DeFronzo iD

Diabetes, Obesity and Metabolism · 2023-02 · 25 (2) · 426-434

DOI: 10.1111/dom.14885 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 04.11.2022. Verfasst von Alexander J Moody und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Texas Health Science Center, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Thiazolidinediones. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIA NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To examine the effect of pioglitazone on epicardial (EAT) and paracardial adipose tissue (PAT) and measures of diastolic function and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM).

Methods

Twelve patients with T2DM without clinically manifest cardiovascular disease and 12 subjects with normal glucose tolerance (NGT) underwent cardiac magnetic resonance imaging to quantitate EAT and PAT and diastolic function before and after pioglitazone treatment for 24 weeks. Whole‐body insulin sensitivity was measured with a euglycaemic insulin clamp and the Matsuda Index (oral glucose tolerance test).

Results

Pioglitazone reduced glycated haemoglobin by 0.9% ( P < 0.05), increased HDL cholesterol by 7% ( P < 0.05), reduced triacylglycerol by 42% ( P < 0.01) and increased whole‐body insulin‐stimulated glucose uptake by 71% ( P < 0.01) and Matsuda Index by 100% ( P < 0.01). In patients with T2DM, EAT ( P < 0.01) and PAT ( P < 0.01) areas were greater compared with subjects with NGT, and decreased by 9% ( P = 0.03) and 9% ( P = 0.09), respectively, after pioglitazone treatment. Transmitral E/A flow rate and peak left ventricular flow rate (PLVFR) were reduced in T2DM versus NGT ( P < 0.01) and increased following pioglitazone treatment ( P < 0.01‐0.05). At baseline normalized PLVFR inversely correlated with EAT ( r = −0.45, P = 0.03) but not PAT ( r = −0.29, P = 0.16). E/A was significantly and inversely correlated with EAT ( r = −0.55, P = 0.006) and PAT ( r = −0.40, P = 0.05). EAT and PAT were inversely correlated with whole‐body insulin‐stimulated glucose uptake ( r = −0.68, P < 0.001) and with Matsuda Index ( r = 0.99, P < 0.002).

Conclusion

Pioglitazone reduced EAT and PAT areas and improved left ventricular (LV) diastolic function in T2DM. EAT and PAT are inversely correlated (PAT less strongly) with LV diastolic function and both EAT and PAT are inversely correlated with measures of insulin sensitivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Insulin ResistanceThiazolidinedionesHumansPioglitazoneHypoglycemic AgentsBlood GlucoseInsulinPericardiumGlucoseAdipose Tissue

Stichwörter der Autor:innen

diastolic functionepicardial and paracardial fatinsulin sensitivitypioglitazonetype 2 diabetes

Substanzen

PioglitazoneHypoglycemic AgentsThiazolidinedionesBlood GlucoseInsulinGlucose

Autor:innen und Institutionen

  • Department of Radiology, University of Texas Health Science Center, San Antonio, Texas, USA.
  • Diabetes Division, UTHSCSA, San Antonio, Texas, USA.
  • Division of Cardiology, UTHSCSA and South Texas Veterans Health Care System, San Antonio, Texas, USA.
  • Consiglio Nazionale delle Richerche, Pisa, Italy; Diabetes Division, UTHSCSA, San Antonio, Texas, USA.
  • Diabetes Institute, and South Texas Veterans Health Care System, San Antonio, Texas, USA.

ORCID-Profile: Eugenio Cersosimo, Amalia Gastaldelli, Muhammad Abdul-Ghani, Ralph A DeFronzo

Förderung

  • NIDDK NIH HHS
  • NIA NIH HHS
  • National Institutes of Health
  • Takeda Pharmaceuticals North America

Zitieren

APA

Moody, A. J., Molina-Wilkins, M., Clarke, G. D., Merovci, A., Solis-Herrera, C., Cersosimo, E., Chilton, R. J., Iozzo, P., Gastaldelli, A., Abdul-Ghani, M., & DeFronzo, R. A. (2023). Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 25(2), 426-434. https://doi.org/10.1111/dom.14885

Vancouver

Moody AJ, Molina-Wilkins M, Clarke GD, Merovci A, Solis-Herrera C, Cersosimo E, et al. Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2023;25(2):426-434. doi:10.1111/dom.14885

BibTeX
@article{Moody2023,
  author = {Moody, Alexander J and Molina-Wilkins, Marjorie and Clarke, Geoffrey D and Merovci, Aurora and Solis-Herrera, Carolina and Cersosimo, Eugenio and Chilton, Robert J and Iozzo, Patricia and Gastaldelli, Amalia and Abdul-Ghani, Muhammad and DeFronzo, Ralph A},
  title = {Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  volume = {25},
  number = {2},
  pages = {426--434},
  doi = {10.1111/dom.14885}
}
Kostenlos starten →